The Journal of Urology
Volume 182, Issue 6 , Pages 2557-2558 , December 2009

What Should Urologists Know About Osteoporosis?

References 

  1. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892
  2. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study (Study of Osteoporotic Fractures Research Group). Arch Intern Med. 1999;159:1215
  3. Forsen L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int. 1999;10:73
  4. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005
  5. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154
  6. Melton LJ, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol. 2003;169:1747
  7. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897
  8. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745
  9. Smith MR, Morton RA, Wallace H, et al. A phase III randomized controlled trial of toremifene to prevent fractures and other adverse effects of androgen therapy in men with prostate cancer. April 12–16, 2008;Presented at annual meeting of American Association for Cancer Research, San Diego, California.

PII: S0022-5347(09)02517-8

doi: 10.1016/j.juro.2009.09.035

The Journal of Urology
Volume 182, Issue 6 , Pages 2557-2558 , December 2009

Article Tools